title: [Hematopoietic reconstitution on the prognosis of hematological malignancies after allogeneic hematopoietic stem cell transplantation].
abstract: OBJECTIVE
  To analyze the impact of the time to hematopoietic reconstitution on the prognosis of hematological malignancies after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
  
  
  METHODS
  173 patients with hematological malignancies treated with allo-HSCT (excluding umbilical cord blood transplantation) at Peking University first Hospital between 2003 and 2011 were analyzed retrospectively. According to the median time to neutrophil and platelet engraftment, the patients were divided into tow groups. The 5-year overall survival (OS), transplant-related mortality (TRM), relapse rate (RR) and prognostic factors were analyzed.
  
  
  RESULTS
  The quicker neutrophil engraftment group with an estimated 5-year OS rate of 66.63%, 5-year TRM of 21.58% and 5-year RR of 18.65%. The slower neutrophil engraftment group with OS of 61.84%, TRM of 24.14% and RR of 23.57%. Univariate analysis demonstrated that no relationship was found between time to neutrophil engraftment and OS, TRM and RR (P = 0.462, P = 0.893, P = 0.545, respectively). There seems to be a trend toward increasing incidence of OS in quicker platelet engraftment group(OS were 69.44% and 54.31%, respectively), but no significant difference (P = 0.065). TRM were 19.13% and 25.45%, respectively (P = 0.424), RR were 17.36% and 24.71%, respectively (P = 0.251). Multivariate analyses showed that the time to neutrophil engraftment was not a significant risk factor for prognosis, the time to platelet engraftment was an independent risk factor for OS and TRM, but not a significant risk factor for RR. Pre-transplantation disease status was the only independent prognostic factor for RR.
  
  
  CONCLUSIONS
  The time to platelet engraftment was a significant predictor after allo-HSCT. Early platelet engraftment increased OS, which this may be due to decreasing TRM.
authors: Department of Hematology, Peking University First Hospital, Beijing, China.
authors: Yan
authors: Y
authors: Zhang
authors: Han-Yun
authors: HY
authors: Ren
authors: Zhi-Xiang
authors: ZX
authors: Qiu
authors: Mang-Ju
authors: MJ
authors: Wang
authors: Wei-Lin
authors: WL
authors: Xu
authors: Wei
authors: W
authors: Liu
authors: Yuan
authors: Y
authors: Li
authors: Yu-Jun
authors: YJ
authors: Dong
authors: Yue
authors: Y
authors: Yin
authors: Yu-Hua
authors: YH
authors: Sun
authors: Li-Hong
authors: LH
authors: Wang
authors: Jin-Ping
authors: JP
authors: Ou
authors: Wen-Sheng
authors: WS
authors: Wang
authors: Xi-Nan
authors: XN
authors: Cen
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D005260:Female; D019337:Hematologic Neoplasms / Q000175:diagnosis / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D055815:Young Adult